San-chi Chen

Yuanshan Branch
Yilan, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study.

Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study.

Journal: Liver cancer

Published: February 06, 2026

Lenvatinib Added to Nivolumab and Ipilimumab Improves Tumor Control and Progression-Free Survival in Unresectable Hepatocellular Carcinoma.

Lenvatinib Added to Nivolumab and Ipilimumab Improves Tumor Control and Progression-Free Survival in Unresectable Hepatocellular Carcinoma.

Journal: Liver cancer

Published: December 27, 2025

Efficacy of Nivolumab plus Ipilimumab in Advanced Hepatocellular Carcinoma with and without High-Risk Features: An International Multicenter Study.

Efficacy of Nivolumab plus Ipilimumab in Advanced Hepatocellular Carcinoma with and without High-Risk Features: An International Multicenter Study.

Journal: Liver cancer

Published: December 05, 2025

Addition of Intra-Arterial Therapy to Immunotherapy Improves Outcomes in Unresectable Hepatocellular Carcinoma: Taiwan Multicenter Cohort Study.

Addition of Intra-Arterial Therapy to Immunotherapy Improves Outcomes in Unresectable Hepatocellular Carcinoma: Taiwan Multicenter Cohort Study.

Journal: Liver cancer

Published: November 13, 2025

Five years after IMbrave150 with clinical integration of atezolizumab plus bevacizumab in hepatocellular carcinoma.

Five years after IMbrave150 with clinical integration of atezolizumab plus bevacizumab in hepatocellular carcinoma.

Journal: Annals of hepatology

Published: November 11, 2025

Human epidermal growth factor receptor-2, nectin-4, and trophoblast cell surface antigen-2 expression varies significantly across ovarian cancer histotypes.

Human epidermal growth factor receptor-2, nectin-4, and trophoblast cell surface antigen-2 expression varies significantly across ovarian cancer histotypes.

Journal: Taiwanese journal of obstetrics & gynecology

Published: November 03, 2025

Taiwan Academy of Tumor Ablation (TATA) consensus on hepatocellular carcinoma ablation.

Taiwan Academy of Tumor Ablation (TATA) consensus on hepatocellular carcinoma ablation.

Journal: Hepatology international

Published: September 30, 2025

Optimizing Systemic Therapy for Advanced Sarcomas: Outcomes With Gemcitabine, Docetaxel, Cisplatin, and Everolimus in a Retrospective Single-Center Study.

Optimizing Systemic Therapy for Advanced Sarcomas: Outcomes With Gemcitabine, Docetaxel, Cisplatin, and Everolimus in a Retrospective Single-Center Study.

Journal: Cancer medicine

Published: September 02, 2025

Machine Learning-Based Survival Analysis for Patients Receiving Lenvatinib for Unresectable Hepatocellular Carcinoma.

Machine Learning-Based Survival Analysis for Patients Receiving Lenvatinib for Unresectable Hepatocellular Carcinoma.

Journal: Journal of hepatocellular carcinoma

Published: August 15, 2025

Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study.

Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: July 14, 2025

Circulating miRNAs as potentially predictive biomarkers for chemoimmunotherapy in advanced biliary tract cancer: a post-hoc analysis of the phase II T1219 study.

Circulating miRNAs as potentially predictive biomarkers for chemoimmunotherapy in advanced biliary tract cancer: a post-hoc analysis of the phase II T1219 study.

Journal: NPJ precision oncology

Published: May 04, 2025

Molecular profiling of circulating tumor cells guides effective EGFR inhibitor treatment in advanced hepatocellular carcinoma: a case report.

Molecular profiling of circulating tumor cells guides effective EGFR inhibitor treatment in advanced hepatocellular carcinoma: a case report.

Journal: Frontiers in oncology

Published: April 09, 2025

Showing 1-12 of 58

Last Updated: 09/26/2026